- Home
- UMAC vs DBVT Comparison
UMAC vs DBVT Comparison
Compare UMAC & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UMAC
- DBVT
- Stock Information
- Founded
- UMAC 2019
- DBVT 2002
- Country
- UMAC United States
- DBVT France
- Employees
- UMAC N/A
- DBVT N/A
- Industry
- UMAC
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UMAC
- DBVT Health Care
- Exchange
- UMAC Nasdaq
- DBVT Nasdaq
- Market Cap
- UMAC 267.7M
- DBVT 289.8M
- IPO Year
- UMAC 2024
- DBVT N/A
- Fundamental
- Price
- UMAC $9.88
- DBVT $9.99
- Analyst Decision
- UMAC Strong Buy
- DBVT Buy
- Analyst Count
- UMAC 2
- DBVT 4
- Target Price
- UMAC $19.00
- DBVT $14.81
- AVG Volume (30 Days)
- UMAC 2.8M
- DBVT 33.5K
- Earning Date
- UMAC 08-14-2025
- DBVT 07-29-2025
- Dividend Yield
- UMAC N/A
- DBVT N/A
- EPS Growth
- UMAC N/A
- DBVT N/A
- EPS
- UMAC N/A
- DBVT N/A
- Revenue
- UMAC $7,701,550.00
- DBVT $3,800,000.00
- Revenue This Year
- UMAC $100.69
- DBVT $1,743.46
- Revenue Next Year
- UMAC $93.15
- DBVT $1,044.34
- P/E Ratio
- UMAC N/A
- DBVT N/A
- Revenue Growth
- UMAC 279.38
- DBVT N/A
- 52 Week Low
- UMAC $1.28
- DBVT $2.21
- 52 Week High
- UMAC $23.62
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- UMAC 50.39
- DBVT 54.55
- Support Level
- UMAC $9.46
- DBVT $9.33
- Resistance Level
- UMAC $11.38
- DBVT $10.10
- Average True Range (ATR)
- UMAC 0.77
- DBVT 0.68
- MACD
- UMAC -0.07
- DBVT 0.05
- Stochastic Oscillator
- UMAC 47.63
- DBVT 61.16
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.